

Medicir

Efficacy and safety evaluation of fludarabinebased chemotherapy regimen for patients with non-Hodgkin lymphoma

A meta-analysis

Xiaoping Zhang, MD, Zheng Ge, MD, Baoan Chen, MD, Ran Liu, MD, Chong Gao, MM st

Abstract

This meta-analysis was performed to evaluate the efficacy and safety of fludarabine (F)-based regimen for the treatment of non-Hodgkin lymphoma (NHL) compared with other regimens with no F contained.

PubMed, Embase, Cochrane Library, Wanfang, VIP, and CNKI databases were searched to identify eligible literatures. R software version 3.12 was used for statistical analysis. Odds ratio (OR) with 95% confidence interval (CI) were utilized to express the complete response, overall response and adverse events outcomes. Egger test was carried out to examine the publication bias and sensitivity analysis was performed to evaluate the stability of our results.

Twelve eligible literatures consisting of 1587 patients were included in this study. Greater complete response (OR = 1.66, 95% CI: 0.98–2.80) and overall response (OR = 1.38, 95% CI: 0.85–2.24) were found for patients who received F-based regimen than those received other regimens, although the results were not statistically significant. In addition, F-based regimen was associated with significantly lower risk of adverse events compared with other regimens (OR = 0.46, 95% CI: 0.28–0.74). Results of subgroup analysis showed that significantly lower incidence was presented only for constipation among the 7 specific adverse events (OR = 0.03, 95% CI: 0.01–0.14).

F-based chemotherapy regimen was an effective and well-tolerated treatment for patients with NHL.

Abbreviations: BR = bendamustine, rituximab, CdA = cladribine, CHOP = cyclophosphamide, doxorubicin, vincristine, prednisone, CHVP = cyclophosphamide, doxorubicin, vindesine, prednisone, CI = confidence interval, CVP = cyclophosphamide, vincristine, prednisone, EPOCH = etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, F = fludarabine, FI = fludarabine, ifosfamide, FM = fludarabine, mitoxantrone, FMD = fludarabine, mitoxantrone, dexamethasone, FR = fludarabine, rituximab, NHL = non-Hodgkin lymphoma, OR = odds ratio, PFS = progression-free survival, RCTVP = rituximab, cyclophosphamide, pirarubicin, vindesine, prednisone, RFT = rituximab, fludarabine, pirarubicin.

Keywords: adverse events, complete response, fludarabine, meta-analysis, non-Hodgkin lymphoma, overall response

1. Introduction

The non-Hodgkin lymphoma (NHL) is a group of heterogeneous neoplasms which develops usually in lymphoid tissues but can occur in almost any tissue.^[1] Approximately, 85% to 90% NHL derives from B lymphocytes and the remainder arises from T

Funding: This work was supported by Health Science and Technology Plan Projects of Jiangsu Province (Grant No. H201336).

The authors have no conflicts of interest to disclose.

Department of Hematology, Zhongda Hospital, Medical School, Southeast University, Nanjing, Jiangsu, China.

* Correspondence: Chong Gao, Department of Hematology, Zhongda Hospital, Medical School, Southeast University, 87 Dingjiaqiao, Gulou District, Nanjing, Jiangsu 210009, China (e-mail: rong58321088@163.com).

Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Medicine (2017) 96:33(e7781)

Received: 10 April 2017 / Received in final form: 7 July 2017 / Accepted: 21 July 2017

http://dx.doi.org/10.1097/MD.000000000007781

lymphocytes or NK lymphocytes.^[2] Under the most recent World Health Organization classification revised in 2016,^[3] over 60 specific subtypes of NHL are recognized in which diffuse large B cell lymphoma, follicular lymphoma, and mucosa-associated lymphoid tissue lymphoma occur most frequently. NHL makes up about 4.6% of all cancer diagnoses and is the fifth or sixth common cancer in women or men.^[1] Overall, NHL is a curable tumor that needs effective treatments.

Chemotherapy is one of the effective treatments for NHL in addition to radiation therapy, immunotherapy, and radioimmunotherapy.^[4–6] Various chemotherapy regimens such as CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) and CVP (cyclophosphamide, vincristine, prednisone) have high efficiency but are associated with poor progression-free survival (PFS).^[7–9] The disease relapses inevitably, and multiple cycles of same regimen are commonly performed to achieve further remission.^[10] In contrast, fludarabine (F), a purine analog has been reported to have a helpful influence on median PFS^[10] and also presents a relatively satisfactory clinical efficacy on relapsed and indolent NHL.^[11,12] Furthermore, F-based regimen is strongly recommended by National Comprehensive Cancer Network as a second-line treatment.

However, controversies exist regarding the efficacy and safety of F-based chemotherapy regimen for patients with NHL. Klasa et al^[10] have reported the superiority of this regimen on median PFS. In addition, it is suggested as a safe regimen with negligible

Editor: Won Sup Lee.

complications by several clinical trials.^[13,14] However, no significant improvement on PFS is detected in the study of Zinzani et al,^[15] and it is accused to be unbearable for the reason of severe toxicity.^[16] Therefore, a meta-analysis is urgently needed to achieve a comprehensive conclusion, which is rarely studied by other investigators.

Meta-analysis is an analytical technique that combines the results of multiple studies, and it increases the sample size and thus the power to study effects of interest.^[17] In this study, a pairwise metaanalysis was performed to evaluate the efficacy and safety of Fbased chemotherapy regimen for the treatment of NHL compared with other chemotherapy regimens which did not contain F.

2. Methods

2.1. Data acquisition and search strategy

A systematic literature search was conducted on PubMed, Embase, Cochrane Library, Wanfang, VIP, and CNKI databases. Additionally, reference lists of relevant literatures were also searched manually to identify eligible literatures. Key words included: fludarabine, non-Hodgkin lymphoma, and non-Hodgkin's lymphoma. Relevant studies were obtained until January 2017, and there was no language restriction.

2.2. Selection criteria

Inclusion criteria were: full-published articles in Chinese or English; patients with NHL; patients in intervention group received single F chemotherapy or F-based chemotherapy regimen, such as FM (fludarabine, mitoxantrone), RFT (rituximab, fludarabine, pirarubicin), FMD (fludarabine, mitoxantrone, dexamethasone), FI (fludarabine, ifosfamide), and FR (fludarabine, rituximab); patients in control group received other chemotherapy regimens with no F contained, such as CHOP, CVP, CHVP (cyclophosphamide, doxorubicin, vindesine, prednisone), BR (bendamustine, rituximab), RCTVP (rituximab, cyclophosphamide, pirarubicin, vindesine, prednisone), CdA (cladribine), and EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin); parameters regarding the efficacy and safety could be extracted. Reviews, reports, comments, and letters were excluded for the final analysis.

2.3. Data extraction

Data were extracted by 2 investigators from the eligible literatures independently, such as name of first author, year of publication, location of study, year of study, the specific subtypes of NHL, number of patients, and demographic characteristics (sex ratio, age, etc.). Disagreements were settled by group discussion with a third investigator.

2.4. Statistical analysis

The meta-analysis was performed by using R software version 3.12 (R Foundation for Statistical Computing, Beijing, China, meta package). Odds ratio (OR) with 95% confidence interval (CI) were utilized to evaluate the effect of chemotherapy for all dichotomous outcomes. The potential heterogeneity was assessed by Q statistic^[18] and I^2 . A random-effects model was used to pool the effect size if significant heterogeneity was detected (P < .05 or $I^2 > 50\%$), otherwise, a fixed-effects model was adopted.^[19] Egger test and funnel plot were carried out to examine the publication bias,^[20] and trim and fill method was applied to

recount the effect size if publication bias was detected.^[21] Furthermore, the sensitivity analysis was conducted by removing one literature at a time to evaluate the stability of our results.^[20]

3. Results

3.1. Eligible literatures

Figure 1 shows the flow diagram of literature selection. A total of 1069 literatures (348 in PubMed, 453 in Embase, 102 in Cochrane Library, 49 in Wanfang, 55 in VIP, and 62 in CNKI database) were obtained by using the search strategy. After removing 498 duplicates and 463 irrelevant articles, a full-text review was applied to the remaining 108 articles. Ninety-six articles (15 letters, 16 case series or reports, 33 reviews, 11 articles with irrelevant data, 14 articles without clear clarification of the kind of chemotherapy in control group and 7 reduplicative studies) were further excluded. Finally, 12 eligible studies were included in this meta-analysis.^[10,15,22–31]

The characteristics of all eligible literatures are listed in Table 1. A total of 1587 patients (804 patients in intervention group and 783 patients in control group) were included in this study. Studies were conducted between 1993 and 2014, and published between 1999 and 2015. Most of the patients suffered from indolent, advanced, or relapsed NHL. Locations of studies included Italy, France, Germany, Canada, and China. Age of patients differed obviously among different literatures, but no significant difference was found between 2 groups in every single literature. Sex distribution between the intervention and control groups was similarly balanced in every eligible literature. Follicular NHL took up a large proportion among all specific subtypes of NHL for patients enrolled in our study. In addition, most of the patients were diagnosed as III or IV stage according to the Ann Arbor staging system.

3.2. Complete response

Evidence of heterogeneity was shown ($I^2 = 76.6\%$, P < .0001) across the 11 studies^[10,15,22–27,29–31] that reported complete response data, thus a random-effects model was applied to calculate the pooled effect size. Pooled estimates indicated that patients in intervention group obtained greater complete response than those in control group (OR = 1.66, 95% CI: 0.98–2.80), but the results did not reach statistical significance (Fig. 2A). Among




Figure 1. Flow chart of study selection.


Table 1 Characteristics of eligible studies.

Author	Publication year	Location	Style	Study year	Group	N	Median age, years (range)	Gender (M/F)	Follicular NHL	Ann Arbor stage (II/III/IV)
Foussard C	2005	France	Advanced low-grade	1995.11-1999.12	FM	72	66 (55-75)	35/37	44	3/9/60
					CHVP	72	65.5 (55-75)	38/34	42	3/7/62
Hagenbeek A	2006	NA	Low-grade malignant	1993-1997	F	194	57 (24-76)	104/90	56	0/47/146
					CVP	187	55 (28-79)	98/88	56	0/42/144
Hou Y	2012	China	Indolent	2002.1-2010.12	RFT	127	62 (21-78)	69/58	106	44/83 (III, IV)
					RCTVP	121	60 (22-80)	63/58	101	46/75 (III, IV)
Klasa RJ	2002	Canada	Recurrent low-grade	1993.10-1996.12	F	47	58 (32-81)	27/20	12	1/15/29
					CVP	44	54 (36-77)	19/25	18	4/14/26
Rummel M	2016	Germany	Relapsed indolent	2003.10-2010.8	FR	105	66.4 (59.3-73.7)	NA	53	0/25/62
					BR	114	68.5 (59.0-74.0)	NA	58	0/25/80
Tondini C	2000	Italy	Low-grade	1993.1-1997.7	F	25	NA	NA	NA	NA
					CdA	29	NA	NA	NA	NA
Zinzani PL	2004	Italy	Follicular lymphoma	1999.10-2002.4	FM	72	52 (26-70)	37/35	72	12/16/44
					CHVP	68	54 (31-70)	38/30	68	8/14/46
Sweetenham J	1999	UK	Indolent B-cell	1977-1997	F	50	Median age: 62.5	NA	NA	2/48 (III, IV)
					CHOP	48	Median age: 59	NA	NA	2/46 (III, IV)
Yan-hong H	2015	China	NA	2011.3-2014.4	FMD	43	24-68	49/37	NA	NA
					CHVP	43			NA	NA
Xue-dong Y	2013	China	Relapsed indolent	2010.1-2012.9	FMD	16	41.6±8.9	19/13	NA	NA
					EPOCH	16			NA	NA
Chang-yun Y	2009	China	Relapsed	2007.1-2008.12	FMD	17	40.6 (28-61)	10/7	NA	NA
					EPOCH	14	42.3 (30-63)	9/5	NA	NA
Chun-sen W	2007	China	Relapsed indolent	2003.5-2005.11	FI	16	53.3 (32.0-70.0)	19/11	18	NA
					CVP	16				NA

BR=bendamustine, rituximab, CdA=cladribine, CHOP=cyclophosphamide, doxorubicin, vincristine, prednison, CHVP=cyclophosphamide, doxorubicin, vincristine, prednisone, CHVP=cyclophosphamide, doxorubicin, F=fludarabine, FI=fludarabine, rituximab, M/F=male/female, NA=not available, NHL=non-Hodgkin lymphoma, RCTVP=rituximab, cyclophophamide, pirarubicin, vindesine, prednisone, RFT=rituximab, fludarabine, pirarubicin.

Study	Experim		Events	ntrol	00	ds Ratio	0	२ 0	5%-CI	W(fixed)	W(random
olddy	Events	iotai	Lyonto	Total		1.8	0		070 01	W(IIXCU)	Witandom
Foussard C 2005	43	72	22	72		-	- 3.3	7 [1.69	; 6.70]	6.9%	9.4%
Hagenbeek A1 200	6 34	105	15	89			2.3	6 [1.19	; 4.71]	8.6%	9.3%
Hagenbeek A2 200	6 41	194	13	187				9 [1.85		8.2%	9.5%
Hou Y1 2012	47	99	56	102		•+-8		4 [0.43		22.7%	9.99
Hou Y2 2012	8	28	3	19		- E.		3 [0.49		2.0%	5.9%
Klasa RJ 2002	4	47	3	44				7 [0.27		2.2%	5.69
Rummel M 2015	18	105	46	114				1 [0.16		28.6%	9.69
Tondini C 2000	12	25	11	29	1000	1		1 [0.51		4.1%	7.5%
Zinzani PL 2004	49	72	29	68		1		7 [1.44		7.5%	9.39
Hui YH 2015	49	43	29	43				•		3.1%	7.6%
	4	16	5	16		. 8 .		0 [1.14			5.6%
Yang XD 2013						· .		3 [0.16		2.9%	
Yang CY 2009	5	17	3	14				3 [0.29		1.8%	5.3%
Wang CS 2007	6	16	3	16			2.6	0 [0.52;	13.04]	1.5%	5.4%
Fixed effect mode	1	839		813		\diamond	1.5	2 [1.22	1.901	100%	-
Random effects m				0.0				6 [0.98			100%
Heterogeneity: I-squa		-square	ed=0 6365	p<0.000)1	E.	1.0	0 [0.00	, 2.00]		100.
fictorogeneity: r sque	100 10.070, 100	oquare	u 0.0000	, p .0.000	ř í – – –	- <u> "</u>					
A		12			0.1 0.5		10				
	Experim Events			ontrol		1 2 ds Ratio		R 9	5%-CI	W(fixed)	W(random
A Study			Co Events	ontrol			10 O	R 9	5%-CI	W(fixed)	W(random
				ontrol			0	R 9 4 [1.24		W(fixed) 5.5%	
Study	Events 58	Total	Events	ontrol Total			O 2.6		; 5.59]	. ,	9.19
Study Foussard C 2005	Events 58 6 73	Total 72	Events 44	ontrol Total 72			0 2.6 1.7	4 [1.24	; 5.59] ; 3.21]	5.5%	9.19 10.09
Study Foussard C 2005 Hagenbeek A1 200 Hagenbeek A2 200	Events 58 6 73	Total 72 105	Events 44 50	ontrol Total 72 89			0 2.6 1.7 1.4	4 [1.24 8 [0.99 3 [0.92	; 5.59] ; 3.21] ; 2.24]	5.5% 10.7% 21.0%	9.19 10.09 10.69
Study Foussard C 2005 Hagenbeek A1 200 Hagenbeek A2 200 Hou Y1 2012	Events 58 6 73 6 63 71	Total 72 105 194 99	Events 44 50 47 72	ntrol Total 72 89 187 102			O 2.6 1.7 1.4 1.0	4 [1.24 8 [0.99 3 [0.92 6 [0.57	; 5.59] ; 3.21] ; 2.24] ; 1.95]	5.5% 10.7% 21.0% 13.0%	9.19 10.09 10.69 9.99
Study Foussard C 2005 Hagenbeek A1 200 Hagenbeek A2 200 Hou Y1 2012 Hou Y2 2012	Events 58 6 73 6 63 71 17	Total 72 105 194 99 28	Events 44 50 47 72 7	ntrol Total 72 89 187 102 19			0 2.6 1.7 1.4 1.0 2.6	4 [1.24 8 [0.99 3 [0.92 6 [0.57 5 [0.80	; 5.59] ; 3.21] ; 2.24] ; 1.95] ; 8.81]	5.5% 10.7% 21.0% 13.0% 2.1%	9.19 10.09 10.69 9.99 6.89
Study Foussard C 2005 Hagenbeek A1 200 Hagenbeek A2 200 Hou Y1 2012 Hou Y2 2012 Klasa RJ 2002	Events 58 6 73 6 63 71 17 30	Total 72 105 194 99 28 47	Events 44 50 47 72 7 23	ntrol Total 72 89 187 102 19 44			O 2.6 1.7 1.4 1.0 - 2.6 1.6	4 [1.24 8 [0.99 3 [0.92 6 [0.57 5 [0.80 1 [0.70	; 5.59] ; 3.21] ; 2.24] ; 1.95] ; 8.81] ; 3.73]	5.5% 10.7% 21.0% 13.0% 2.1% 5.6%	9.19 10.09 10.69 9.99 6.89 8.79
Study Foussard C 2005 Hagenbeek A1 200 Hagenbeek A2 200 Hou Y1 2012 Hou Y2 2012 Klasa RJ 2002 Rummel M 2015	Events 58 6 73 6 63 71 17 30 54	Total 72 105 194 99 28 47 105	Events 44 50 47 72 7 23 94	ntrol Total 72 89 187 102 19 44 114		ds Ratio	0 2.6 1.7 1.4 1.0 - 2.6 1.6 0.2	4 [1.24 8 [0.99 3 [0.92 6 [0.57 5 [0.80 1 [0.70 3 [0.12	; 5.59] ; 3.21] ; 2.24] ; 1.95] ; 8.81] ; 3.73] ; 0.42]	5.5% 10.7% 21.0% 13.0% 2.1% 5.6% 28.4%	9.19 10.09 10.69 9.99 6.89 8.79 9.89
Study Foussard C 2005 Hagenbeek A1 200 Hou Y1 2012 Hou Y1 2012 Klasa RJ 2002 Rummel M 2015 Tondini C 2000	Events 58 6 73 6 63 71 17 30 54 17	Total 72 105 194 99 28 47 105 25	Events 44 50 47 72 7 23 94 20	ontrol Total 72 89 187 102 19 44 114 29			0 2.6 1.7 1.4 1.0 - 2.6 1.6 0.2 0.9	4 [1.24 8 [0.99 3 [0.92 6 [0.57 5 [0.80 1 [0.70 3 [0.12 6 [0.30	; 5.59] ; 3.21] ; 2.24] ; 1.95] ; 8.81] ; 3.73] ; 0.42] ; 3.02]	5.5% 10.7% 21.0% 13.0% 2.1% 5.6% 28.4% 3.8%	9.19 10.09 10.69 9.99 6.89 8.79 9.89 7.09
Study Foussard C 2005 Hagenbeek A1 200 Hou Y1 2012 Hou Y1 2012 Klasa RJ 2002 Rummel M 2015 Tondini C 2000 Zinzani PL 2004	Events 58 6 73 6 63 71 17 30 54 17 69	Total 72 105 194 99 28 47 105 25 72	Events 44 50 47 72 7 23 94 20 67	ntrol Total 72 89 187 102 19 44 114 29 68 -		ds Ratio	O 2.6 1.7 1.4 1.0 - 2.6 1.6 0.2 0.9 0.3	4 [1.24 8 [0.99 3 [0.92 6 [0.57 5 [0.80 1 [0.70 3 [0.12 6 [0.30 4 [0.03	; 5.59] ; 3.21] ; 2.24] ; 1.95] ; 8.81] ; 3.73] ; 0.42] ; 3.02] ; 3.38]	5.5% 10.7% 21.0% 13.0% 2.1% 5.6% 28.4% 3.8% 1.9%	9.19 10.09 10.69 9.99 6.89 8.79 9.89 7.09 3.29
Study Foussard C 2005 Hagenbeek A1 200 Hou Y1 2012 Hou Y1 2012 Klasa RJ 2002 Rummel M 2015 Tondini C 2000 Zinzani PL 2004 Hui YH 2015	Events 58 6 73 6 63 71 17 30 54 17 69 36	Total 72 105 194 99 28 47 105 25 72 43	Events 44 50 47 72 7 23 94 20 67 23	ntrol Total 72 89 187 102 19 44 114 29 68 - 43		ds Ratio	O 2.6 1.7 1.4 1.0 - 2.6 0.2 0.9 0.3 - 4.4	4 [1.24 8 [0.99 3 [0.92 6 [0.57 5 [0.80 1 [0.70 3 [0.12 6 [0.30 4 [0.03 7 [1.63;	; 5.59] ; 3.21] ; 2.24] ; 1.95] ; 8.81] ; 3.73] ; 0.42] ; 3.02] ; 3.38] 12.24]	5.5% 10.7% 21.0% 13.0% 2.1% 5.6% 28.4% 3.8% 1.9% 2.4%	9.19 10.09 10.69 9.99 6.89 8.79 9.89 7.09 3.29 7.89
Study Foussard C 2005 Hagenbeek A1 200 Hou Y1 2012 Hou Y1 2012 Klasa RJ 2002 Rummel M 2015 Tondini C 2000 Zinzani PL 2004 Hui YH 2015 Yang XD 2013	Events 58 6 73 6 63 71 17 30 54 17 69 36 9	Total 72 105 194 99 28 47 105 25 72 43 16	Events 44 50 47 72 7 23 94 20 67 23 10	ntrol Total 72 89 187 102 19 44 114 29 68 – 43 16		ds Ratio	0 2.6 1.7 1.4 1.0 - 2.6 1.6 0.2 0.9 0.3 - 0.3 - 4.4 0.7	4 [1.24 8 [0.99 3 [0.92 6 [0.57 5 [0.80 1 [0.70 3 [0.12 6 [0.30 4 [0.03 7 [1.63; 7 [0.19	; 5.59] ; 3.21] ; 2.24] ; 1.95] ; 8.81] ; 3.73] ; 0.42] ; 3.02] ; 3.38] 12.24] ; 3.17]	5.5% 10.7% 21.0% 13.0% 2.1% 5.6% 28.4% 3.8% 1.9% 2.4% 2.8%	9.19 10.09 10.69 9.99 6.89 8.79 9.89 7.09 3.29 7.89 5.99
Study Foussard C 2005 Hagenbeek A1 200 Hou Y1 2012 Hou Y1 2012 Klasa RJ 2002 Rummel M 2015 Tondini C 2000 Zinzani PL 2004 Hui YH 2015 Yang XD 2013 Yang CY 2009	Events 58 6 73 6 63 71 17 30 54 17 69 36 9 12	Total 72 105 194 99 28 47 105 25 72 43 16 17	Events 44 50 47 72 7 23 94 20 67 67 23 10 7	ntrol Total 72 89 187 102 19 44 114 29 68 43 16 14		ds Ratio	O 2.6 1.7 1.4 1.0 - 2.6 1.6 0.2 0.9 0.3 - 4.4 0.7 - 2.4	4 [1.24 8 [0.99 3 [0.92 6 [0.57 5 [0.80 1 [0.70 3 [0.12 6 [0.30 4 [0.03 7 [1.63; 7 [0.19 0 [0.55;	; 5.59] ; 3.21] ; 2.24] ; 1.95] ; 8.81] ; 3.73] ; 0.42] ; 3.02] ; 3.38] 12.24] ; 3.17] 10.53]	5.5% 10.7% 21.0% 13.0% 2.1% 5.6% 28.4% 3.8% 1.9% 2.4% 2.8% 1.5%	9.19 10.09 10.69 9.99 6.89 8.79 9.89 7.09 3.29 7.89 5.99 5.69
Study Foussard C 2005 Hagenbeek A1 200 Hou Y1 2012 Hou Y1 2012 Klasa RJ 2002 Rummel M 2015 Tondini C 2000 Zinzani PL 2004 Hui YH 2015 Yang XD 2013	Events 58 6 73 6 63 71 17 30 54 17 69 36 9	Total 72 105 194 99 28 47 105 25 72 43 16	Events 44 50 47 72 7 23 94 20 67 23 10	ntrol Total 72 89 187 102 19 44 114 29 68 – 43 16		ds Ratio	O 2.6 1.7 1.4 1.0 - 2.6 1.6 0.2 0.9 0.3 - 4.4 0.7 - 2.4	4 [1.24 8 [0.99 3 [0.92 6 [0.57 5 [0.80 1 [0.70 3 [0.12 6 [0.30 4 [0.03 7 [1.63; 7 [0.19	; 5.59] ; 3.21] ; 2.24] ; 1.95] ; 8.81] ; 3.73] ; 0.42] ; 3.02] ; 3.38] 12.24] ; 3.17] 10.53]	5.5% 10.7% 21.0% 13.0% 2.1% 5.6% 28.4% 3.8% 1.9% 2.4% 2.8%	9.19 10.09 10.69 9.99 6.89 8.79 9.89 7.09 3.29 7.89 5.99 5.69
Study Foussard C 2005 Hagenbeek A1 200 Hou Y1 2012 Hou Y1 2012 Klasa RJ 2002 Rummel M 2015 Tondini C 2000 Zinzani PL 2004 Hui YH 2015 Yang XD 2013 Yang CY 2009 Wang CS 2007	Events 58 6 73 6 63 71 17 30 54 17 69 36 9 12 12	Total 72 105 194 99 28 47 105 25 72 43 16 17 16	Events 44 50 47 72 7 23 94 20 67 67 23 10 7	ntrol Total 72 89 187 102 19 44 114 29 68 43 16 14 16		ds Ratio	O 2.6 1.7 1.4 1.6 0.2 0.3 - 4.4 - 2.4 - 3.0	4 [1.24 8 [0.99 3 [0.92 6 [0.57 5 [0.80 1 [0.70 3 [0.12 6 [0.30 4 [0.03 7 [1.63; 7 [0.19 0 [0.55; 0 [0.67;	; 5.59] ; 3.21] ; 2.24] ; 1.95] ; 8.81] ; 3.73] ; 0.42] ; 3.02] ; 3.38] 12.24] 12.24] ; 3.17] 10.53] 13.40]	5.5% 10.7% 21.0% 13.0% 2.1% 5.6% 28.4% 3.8% 1.9% 2.4% 2.8% 1.5% 1.3%	9.19 10.09 10.69 9.99 6.89 8.79 9.89 7.09 3.29 7.89 5.99 5.69
Study Foussard C 2005 Hagenbeek A1 200 Hou Y1 2012 Hou Y1 2012 Klasa RJ 2002 Rummel M 2015 Tondini C 2000 Zinzani PL 2004 Hui YH 2015 Yang XD 2013 Yang CY 2009 Wang CS 2007 Fixed effect mode	Events 58 6 73 6 63 71 17 30 54 17 69 36 9 12 12 12	Total 72 105 194 99 28 47 105 25 72 43 16 17	Events 44 50 47 72 7 23 94 20 67 67 23 10 7	ntrol Total 72 89 187 102 19 44 114 29 68 43 16 14		ds Ratio	O 2.6 1.7 1.4 1.0 - 2.6 1.6 0.2 0.9 0.3 - 4.4 0.7 - 2.4 - 3.0 - 1.2	4 [1.24 8 [0.99 3 [0.92 6 [0.57 5 [0.80 1 [0.70 3 [0.12 6 [0.30 4 [0.03 7 [1.63; 7 [0.13] 0 [0.55; 0 [0.67; 3 [1.00	; 5.59] ; 3.21] ; 2.24] ; 1.95] ; 8.81] ; 3.73] ; 0.42] ; 3.02] ; 3.38] 12.24] ; 3.17] 10.53] 13.40] ; 1.52]	5.5% 10.7% 21.0% 13.0% 2.1% 5.6% 28.4% 3.8% 1.9% 2.4% 2.8% 1.5%	9,11 10.09 10.69 9,99 6.89 8,77 9,88 7.09 3,22 7,89 5,99 5,66 5,59
Study Foussard C 2005 Hagenbeek A1 200 Hou Y1 2012 Hou Y1 2012 Klasa RJ 2002 Rummel M 2015 Tondini C 2000 Zinzani PL 2004 Hui YH 2015 Yang XD 2013 Yang CY 2009 Wang CS 2007 Fixed effect mode Random effects m	Events 58 6 73 6 63 71 17 30 54 17 69 36 9 12 12 12	Total 72 105 194 99 28 47 105 25 72 43 105 72 43 16 17 16 839	Events 44 50 47 72 7 23 94 20 67 67 23 10 7 8	ntrol Total 72 89 187 102 19 44 114 29 68 - 43 16 14 16 813		ds Ratio	O 2.6 1.7 1.4 1.0 - 2.6 1.6 0.2 0.9 0.3 - 4.4 0.7 - 2.4 - 3.0 - 1.2	4 [1.24 8 [0.99 3 [0.92 6 [0.57 5 [0.80 1 [0.70 3 [0.12 6 [0.30 4 [0.03 7 [1.63; 7 [0.19 0 [0.55; 0 [0.67;	; 5.59] ; 3.21] ; 2.24] ; 1.95] ; 8.81] ; 3.73] ; 0.42] ; 3.02] ; 3.38] 12.24] ; 3.17] 10.53] 13.40] ; 1.52]	5.5% 10.7% 21.0% 13.0% 2.1% 5.6% 28.4% 3.8% 1.9% 2.4% 2.8% 1.5% 1.3%	9,11 10.09 10.69 9,99 6.89 8,77 9,88 7.09 3,22 7,89 5,99 5,66 5,59
Study Foussard C 2005 Hagenbeek A1 200 Hou Y1 2012 Hou Y1 2012 Klasa RJ 2002 Rummel M 2015 Tondini C 2000 Zinzani PL 2004 Hui YH 2015 Yang XD 2013 Yang CY 2009 Wang CS 2007 Fixed effect mode	Events 58 6 73 6 63 71 17 30 54 17 69 36 9 12 12 12	Total 72 105 194 99 28 47 105 25 72 43 105 72 43 16 17 16 839	Events 44 50 47 72 7 23 94 20 67 67 23 10 7 8	ntrol Total 72 89 187 102 19 44 114 29 68 - 43 16 14 16 813		ds Ratio	O 2.6 1.7 1.4 1.0 - 2.6 1.6 0.2 0.9 0.3 - 4.4 0.7 - 2.4 - 3.0 - 1.2	4 [1.24 8 [0.99 3 [0.92 6 [0.57 5 [0.80 1 [0.70 3 [0.12 6 [0.30 4 [0.03 7 [1.63; 7 [0.13] 0 [0.55; 0 [0.67; 3 [1.00	; 5.59] ; 3.21] ; 2.24] ; 1.95] ; 8.81] ; 3.73] ; 0.42] ; 3.02] ; 3.38] 12.24] ; 3.17] 10.53] 13.40] ; 1.52]	5.5% 10.7% 21.0% 13.0% 2.1% 5.6% 28.4% 3.8% 1.9% 2.4% 2.8% 1.5% 1.3%	W(random 9.19 10.09 9.99 6.89 8.79 9.89 7.09 3.29 7.88 5.99 5.69 5.59

Figure 2. Forest plots of treatment effect for (A) complete response and (B) overall response.



these 11 studies, only the study of Rummel et al^[27] exhibited significantly worse response for patients in intervention group than those in control group (OR=0.31, 95% CI: 0.16–0.57; Fig. 2A). To be noted, significant difference was shown after omitting this study for the parameter of complete response (OR=2.03, 95% CI: 1.37–2.99; Fig. 3A). No publication bias was detected across the studies (t=0.38, P=.71). As shown in the funnel plot, no publication bias was existed (Fig. 4A).


3.3. Overall response

According to the WHO criteria, overall response rate was defined as the sum of complete response rate and partial response rate. A random-effects model was used to pool the estimates since heterogeneity was detected ($I^2 = 74.8\%$, P < .0001). Pooled estimates suggested that patients in intervention group obtained higher overall response rate

than those in control group (OR = 1.38, 95% CI: 0.85–2.24), but the results had no statistically significant (Fig. 2B). Similar to the complete response, significantly decreased overall response rate was found in intervention group in the study of Rummel et al^[27] (OR=0.23, 95% CI: 0.12–0.42; Fig. 2B), which was unique among the 11 relevant studies.^[10,15,22–27,29–31] Significant difference was also exhibited with the omission of this study for the parameter of overall response (OR=1.66, 95% CI: 1.26–2.18; Fig. 3B). No publication bias was detected across the studies (t=0.60, P=.56). As shown in the funnel plot, no publication bias was existed (Fig. 4B).

3.4. Adverse events

A random-effects model was used since there was heterogeneity for studies related with adverse events ($I^2 = 80.7\%$, P < .0001). Incidence of adverse events was significantly lower for patients in



intervention group than those in control group (OR = 0.46, 95% CI: 0.28–0.74; Fig. 5).

Furthermore, subgroup analysis was performed regarding 7 different adverse events (diarrhea, nausea and vomiting, alopecia, infection, peripheral neurotoxicity, constipation, and fever). Random-effects models were applied to pool estimates for adverse events of alopecia, nausea and vomiting and peripheral neurotoxicity while fixed-effects models were used for other adverse effects. Results of subgroup analysis are listed in Table 2. Significantly decreased incidence was found only in constipation subgroup (OR = 0.03, 95% CI: 0.01-0.14) among the 7 specific adverse events.

Subgroup analysis regarding ages (≥ 60 group and < 60 group) was performed, and the result is shown in Table 3. It showed that there was no statistically significant difference in ≥ 60 group for complete response and overall response, but statistically significant difference was existed in < 60 group for complete response (P < .001) and overall response (P = .0057).

4. Discussion

In the present study, we performed a pairwise meta-analysis to evaluate the efficacy (in terms of complete response and overall response) and safety (in terms of adverse effects) of F-based chemotherapy regimen for the treatment of NHL based on 12 eligible trials. Greater complete response and overall response were found for F-based regimen, but the results were not statistically significant. However, the results reached a statistical significance with the omission of the study of Rummel et al. In addition, patients treated with F-based regimen had significantly decreased incidence of adverse events, but only the outcome of constipation was significant among the 7 specific adverse events according to the subgroup analysis.

F is a member of purine analog family. It yields a metabolite of 2F-ara-ATP under the function of DNA cytosine kinase which interferes the duplication of DNA subsequently by suppressing the activity of DNA polymerase, DNA ligase, and ribonucleotide reductase.^[32] Other agents contained in the regimens had different mechanisms of action, such as cyclophosphamide working as alkylating agent and doxorubicin working as intercalating agent.^[33] Our results showed that F-based regimen performed better on complete response and overall response compared with other regimens, which was in line with a number of clinical trials. Single administration of F was reported to present better complete response and overall response in

Study	Experime Events T			ontrol Total	Odds Ratio	OR	95%-CI	W(fixed)	W(random)
Group = Alopecia					2				
Hagenbeek A2 2006	0	194	2	187		0.19	[0.01; 4.00]	0.6%	1.6%
Hagenbeek A1 2006		105	4	89		0.09	[0.00; 1.70]	1.2%	1.7%
Zinzani PL 2004	10	72	58	68			[0.01; 0.07]	12.7%	3.8%
Hui YH 2015	21	43	11	43		2.78		1.4%	3.9%
Foussard C 2005	24	72	9	72	3 <u>-</u>		[1.49; 8.21]	1.5%	3.9%
Hou Y 2012		127	24	121			[0.50; 1.77]	4.9%	4.2%
Fixed effect model		613		580			[0.46; 0.89]	22.3%	-1.2.70
Random effects model		0.0		000	2*		[0.09; 2.51]		19.0%
Heterogeneity: I-squared=93%, tau-s	squared=3.634, j	p<0.00	001		2	0.47	[0.00, 2.01]		10.070
Group = Constipation					2				
Hagenbeek A2 2006	0	194	2	187		0 10	[0.01; 4.00]	0.6%	1.6%
Zinzani PL 2004	0	72	32	68		0.13		8.2%	1.8%
Hagenbeek A1 2006		105	3	89	1000 2 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		[0.00; 0.13]	0.2%	1.6%
Fixed effect model		371	3	344				9.7%	1.0 %
Random effects model		2/1		344			[0.01; 0.14]	9.170	5.0%
Heterogeneity: I-squared=35.7%, tau	I-squared=1.255	i, p=0.	2111			0.05	[0.01; 0.44]		5.0 %
o					3				
Group = Diarrhea	0	105			2	0.00	10.04. 0.00	0 101	6 504
Rummel M 2015		105	1	114			[0.01; 8.90]	0.4%	1.5%
Hagenbeek A2 2006		194	2	187	2		[0.04; 5.33]	0.5%	2.1%
Hagenbeek A1 2006		105	2	89			[0.12; 6.12]	0.5%	2.5%
Fixed effect model		404		390			[0.15; 2.28]	1.4%	0.40/
Random effects model		0.05			3	0.60	[0.15; 2.38]		6.1%
Heterogeneity: I-squared=0%, tau-so	guared=0, p=0.8	837							
Group = Fever					2				
Hou Y 2012	5	127	4	121		1.20	[0.31; 4.57]	1.0%	3.3%
Foussard C 2005	6	72	10	72			[0.19; 1.64]	2.3%	3.7%
Sweetenham J 1999	9	50	13	48		0.59		2.7%	3.8%
Hui YH 2015	13	43	15	43		0.81		2.6%	3.9%
Fixed effect model		292		284	6		[0.43; 1.20]	8.5%	
Random effects model						0.72	[0.43; 1.21]		14.6%
Heterogeneity: I-squared=0%, tau-so	guared=0, p=0.8	052							
Group = Infection					2				
Hagenbeek A2 2006	1	194	1	187		0.96	[0.06; 15.52]	0.2%	1.8%
Hagenbeek A1 2006		105	4	89	2 		[0.14; 2.87]	1.0%	3.1%
Foussard C 2005	10	72	14	72	2		[0.28; 1.62]	3.0%	3.9%
Rummel M 2015		105	34	114	3		[0.47; 1.54]	5.9%	4.2%
Fixed effect model		476	04	462	ų.		[0.49; 1.24]	10.2%	4.2.70
Random effects model		410		402			[0.49; 1.24]	10.2.70	12.9%
Heterogeneity: I-squared=0%, tau-so	quared=0, p=0.9	572			2	0.110	[0.10, 1.1]		1210 /0
Group = Nausea and vomiting					2				
Hagenbeek A2 2006		194	1	187		0.96	[0.06; 15.52]	0.2%	1.8%
Hagenbeek A1 2006		105	6	89			[0.02; 1.13]	1.6%	2.4%
Zinzani PL 2004	2	72	15	68	;		[0.02; 0.46]		3.1%
Yang CY 2009	6	17	2	14	3		[0.54; 19.75]	0.3%	2.8%
Sweetenham J 1999	10	50	29	48			[0.07; 0.40]	5.8%	3.9%
Klasa RJ 2002	14	47	41	44			[0.01; 0.12]	7.3%	3.3%
Hui YH 2015	26	43	11	43			[1.78; 11.14]	1.1%	3.8%
Rummel M 2015		105	40	114	5		[0.36; 1.15]		4.2%
Fixed effect model		633	40	607	6		[0.33; 0.63]	27.2%	4.2.70
Random effects model		000		007	A A A A A A A A A A A A A A A A A A A		[0.12; 1.31]	d= 1 - d= 70	25.2%
Heterogeneity: I-squared=87.4%, tau	I-squared=2.398	, p<0.	0001			0.00	[0.12, 1.01]		20.270
Group = Peripheral neurotoxic	site				2				
	-	104	4	197	1	0.20	[0 01· 7 00]	0 404	1 50/
Hagenbeek A2 2006		194	1	187			[0.01; 7.90]		1.5%
Zinzani PL 2004	0	72	18	68			[0.00; 0.32]	4.7%	1.8%
Hagenbeek A1 2006		105	1	89			[0.05; 13.73]		1.8%
Klasa RJ 2002 Hou Y 2012	17	47	33	44			[0.08; 0.47]		3.9%
		127	38	121			[0.19; 0.68]		4.2%
Sweetenham J 1999	31	50	20	48			[1.02; 5.13]		4.0%
Fixed effect model		595		557	•		[0.29; 0.62]	20.8%	475.004
Random effects model Heterogeneity: I-squared=79.9%, tau	I-squared=1.362	, p=0.	0001			0.38	[0.12; 1.23]		17.0%
							10.10.0.00	4000	
Fixed effect model	3	384		3224	\$		[0.43; 0.60]	100%	100%
Random effects model Heterogeneity: I-squared=80.7%, tau	-squared=1.344	, p<0.	0001		2	0.46	[0.28; 0.74]		100%
· · · · · · · · · · · · · · · · · · ·			20137074						
						1000			
	Figure 5.	Fore	est plots	s of tr	eatment effect for advers	se event	S.		

untreated NHL patients,^[25] and it showed greater PFS in recurrent NHL patients compared with CVP chemotherapy regimen.^[10] Similar improvement was also shown for combined administration of F-based regimen.^[22,24,26,34]

Among the 7 specific adverse events, only constipation showed a significantly lower incidence of patients treated with F-based chemotherapy regimen in our study. Constipation was a common adverse event for patients treated with various chemotherapy regimens.^[25,35,36] Two relevant clinical trials provided a support for our analysis, which reached an exact consensus of lower risk of constipation for single and combined F chemotherapy.^[15,25]

Subgroup analysis for ages showed that there was no statistically significant difference in ≥ 60 group, but statistically

Subgroup analysis of adverse events.

Adverse events	k	OR	95% CI	<i>ľ</i> ² (%)	Р	Model
Alopecia	6	0.47	0.09-2.51	93.0	<.0001	Random
Constipation	3	0.03	0.01-0.14	35.7	.21	Fixed
Diarrhea	3	0.59	0.15-2.28	0	.88	Fixed
Fever	4	0.72	0.43-1.20	0	.81	Fixed
Infection	4	0.78	0.49-1.24	0	.96	Fixed
Nausea and vomiting	8	0.39	0.12-1.31	87.4	<.0001	Random
Peripheral neurotoxicity	6	0.38	0.12-1.23	79.9	.0001	Random

CI = confidence interval, OR = odds ratio.

Table 3

Subgroup analysis of ages.

		Sample	size	Test of	Test of heterogeneity ^{*,†}					
Variable	Group	Fludarabine	Control	OR (95% CI)	Ζ	Р	Model	Q	Р	<i>l</i> ² (%)
Complete response	≥60	304	307	1.0700 [0.3520-3.2523]	0.12	.9051	R	27.16	<.0001	89
	<60	467	434	2.5272 [1.7850-3.5781]	5.23	<.001	F	4.80	.5694	0
Overall response	≥60	304	307	1.0864 [0.3307-3.5684]	0.14	.8914	R	30.49	<.0001	90.2
	<60	467	434	1.5277 [1.1312–2.0630]	2.76	.0057	F	4.02	.6735	0

CI = confidence interval, F = fixed-effect model, R = random-effects model.

* Random-effects model was used when the P for heterogeneity test <.05, otherwise the fixed-effect model was used.

[†] P < .05 is considered statistically significant for Q statistics; OR = odds ratio.

significant difference was existed in <60 group for complete response and overall response, which suggested that F-based chemotherapy regimen was a more effective treatment for NHL patients <60 years old. However, because age used for the present statistical analysis is an average, more studies about ages are needed in future researches to get more accurate conclusions.

Besides, F may exert its functions on patients with NHL through both distorting the phosphate backbone and also the base pairing mechanism, which is different from alkylating reagent such as cyclophosphamide.^[37] But further studies are needed for the detailed and accurate molecular mechanisms.

To the best of our knowledge, this was the first meta-analysis conducted to evaluate the efficacy and safety of F-based chemotherapy regimen. However, the results should be interpreted under some limitations. Firstly, heterogeneity existed across the trials enrolled in our analysis for assessing complete response, overall response, and adverse events. It might due to several reasons, such as huge age gap of patients, different number of patients, and different study location. The heterogeneity was not settled by subgroup analysis or meta-regression analysis since inadequate data were provided by relevant trials. Secondly, several complications which were referred to frequently for F-based chemotherapy regimen such as myelosuppression and hematological toxic events were not evaluated in our analysis, because less than 2 trials reported the raw data regarding these complications. Thirdly, Rummel et al declared a superiority of bendamustine over F on effectiveness for NHL. Hence, cautious explanation of our conclusion was necessary with respect to the study of Rummel et al. Fourthly, NHL could be derived from B lymphocytes, T lymphocytes, or NK lymphocytes, but there was not information about the origin of NHL in some of the included studies. Thus, we do not know if there is a difference in terms of efficacy and tolerance of F-based regimen between different cell types. Further studies about this question are needed.

In conclusion, F-based chemotherapy regimen was an effective and well-tolerated treatment for patients with NHL, especially for patients <60 years old. Thus, other things being equal, F-based chemotherapy regimen may be the preferred choice for the treatment of NHL in clinical practice. However, large scale of randomized controlled trials is needed to confirm the conclusion.

References

- Evans LS, Hancock BW. Non-Hodgkin lymphoma. Lancet 2003;362: 139–46.
- [2] Shankland KR, Armitage JO, Hancock BW. Non-Hodgkin lymphoma. Lancet 2012;380:848–57.
- [3] Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016;127:2375–90.
- [4] Ansell SM, Armitage J. Non-Hodgkin lymphoma: diagnosis and treatment. Mayo Clin Proc 2005;80:1087–97.
- [5] Till BG, Jensen MC, Wang J, et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 2008;112:2261–71.
- [6] Wiseman GA, Gordon LI, Multani PS, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 2002;99:4336–42.
- [7] Hunault-Berger M, Ifrah N, Solal-Celigny P, et al. Intensive therapies in follicular non-Hodgkin lymphomas. Blood 2002;100:1141–52.
- [8] Heinzelmann F, Ottinger H, Engelhard M, et al. Advanced-stage III/IV follicular lymphoma: treatment strategies for individual patients. Strahlenther Onkol 2010;186:247–54.
- [9] Foussard C, Desablens B, Sensebe L, et al. Is the International Prognostic Index for aggressive lymphomas useful for low-grade lymphoma patients? Applicability to stage III–IV patients. Ann Oncol 1997;8(suppl 1):49–52.
- [10] Klasa RJ, Meyer RM, Shustik C, et al. Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine, and prednisone in patients with recurrent low-grade non-Hodgkin's lymphoma previously treated with an alkylating agent or alkylator-containing regimen. J Clin Oncol 2002;20: 4649–54.

- [11] Rao R, Shammo JM, Enschede SH, et al. The combination of fludarabine, cyclophosphamide, and granulocyte-macrophage colonystimulating factor in the treatment of patients with relapsed chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma. Clin Lymphoma 2005;6:26–30.
- [12] Pigaditou A, Rohatiner AZ, Whelan JS, et al., Fludarabine in low-grade lymphoma. Semin Oncol; 1993, 20, 24–27.
- [13] Velasquez WS, Lew D, Grogan TM, et al. Combination of fludarabine and mitoxantrone in untreated stages III and IV low-grade lymphoma: S9501. J Clin Oncol 2003;21:1996–2003.
- [14] Bordonaro R, Petralia G, Restuccia N, et al. Fludarabine, mitoxantrone and dexamethasone as front-line therapy in elderly patients affected by newly-diagnosed, low-grade non-Hodgkin's lymphomas with unfavorable prognostic factors: results of a phase II study. Leuk Lymphoma 2004;45:93–100.
- [15] Zinzani PL, Pulsoni A, Perrotti A, et al. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. J Clin Oncol 2004;22:2654–61.
- [16] Frewin R, Turner D, Tighe M, et al. Combination therapy with fludarabine and cyclophosphamide as salvage treatment in lymphoproliferative disorders. Br J Haematol 1999;104:612–3.
- [17] Walker E, Hernandez AV, Kattan MW. Meta-analysis: its strengths and limitations. Cleve Clin J Med 2008;75:431–9.
- [18] Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med 1997;127:820-6.
- [19] Feng R-N, Zhao C, Sun C-H, et al. Meta-analysis of TNF 308 G/A polymorphism and type 2 diabetes mellitus. PLoS ONE 2011;6:e18480.
- [20] Kondo N, Bessho H, Negi A. Complement factor H Y402H variant and risk of age-related macular degeneration in Asians: a systematic review and meta-analysis. Ophthalmology 2011;118:339–44.
- [21] Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000;56:455–63.
- [22] Chang-yun Y, Shao-yi C, Zhi-min C. Clinical study on fludarabine-based combined chemotherapy in patients with relapsed non-Hodgkins's lymphoma. Prog Modern Biomed 2009;9:2685–7.
- [23] Chun-sen W, Xiao-dong W, Jin-lin Z. Efficacy of fludarabine combination with ifosfamide for relapsed indolent non-Hodgkin lymphoma. J Leuk Lymphoma 2007;16:280–1.
- [24] Foussard C, Colombat P, Maisonneuve H, et al. Long-term follow-up of a randomized trial of fludarabine-mitoxantrone, compared with cyclophosphamide, doxorubicin, vindesine, prednisone (CHVP), as first-line treatment of elderly patients with advanced, low-grade non-Hodgkin's lymphoma before the era of monoclonal antibodies. Ann Oncol 2005;16:466–72.

- [25] Hagenbeek A. Phase III Intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV Low-grade malignant non-Hodgkin's lymphoma. J Clin Oncol 2006;24:1590–6.
- [26] Hou Y, Wang HQ, Ba Y. Comparison on therapeutic effects of RFT and RCTVP regimen in the treatment of patients with indolent B-cell lymphoma in China. Med Oncol 2012;29:2372–8.
- [27] Rummel M, Kaiser U, Balser C, et al. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, noninferiority phase 3 trial. Lancet Oncol 2016;17:57–66.
- [28] Sweetenham J, Hieke K, Kerrigan M, et al. Fludarabine plus rituximab for patieneatment of relapsed indolent B-cell non-Hodgkin's lymphoma in the UK. Br J Haematol 1999;106:47–54.
- [29] Tondini C, Balzarotti M, Rampinelli I, et al. Fludarabine and cladribine in relapsed/refractory low-grade non-Hodgkin's lymphoma: a phase II randomized study. Ann Oncol 2000;11:231–3.
- [30] Xue-dong Y, Qiang L, Jian-xin Y. Observation of clinical effect on fludarabine-based combined chemotherapy in patients with relapsed and refractory non-Hodgkins's lymphoma. Med Inf 2013;26:338–9.
- [31] Yan-hong H. Curative effect and feasible analysison FND in patients with relapsed non-Hodgkins's lymphoma. Chin J Trauma Disabil Med 2015;23:145–6.
- [32] Zinzani PL, Tani M, Fanti S, et al. A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma. Cancer 2008;112:856–62.
- [33] Di GN, Xiao Y, Erba E, et al. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol 2001;114:800–9.
- [34] Gregory SA, Vose J, Modiano M, et al. Mitoxantrone and fludarabine in the treatment of patients with non-Hodgkin's lymphoma failing primary therapy with a doxorubicinor mitoxantrone-containing regimen. Leuk Lymphoma 2001;40:315–24.
- [35] Friedberg JW, Cohen P, Chen L, et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol 2008;26:204–10.
- [36] Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 2008;26:4473–9.
- [37] Kou Y, Koag M-C, Lee S. N7 methylation alters hydrogen-bonding patterns of guanine in duplex DNA. J Am Chem Soc 2015;137: 14067–70.